Tectonic Therapeutic (NASDAQ:TECX) recently announced positive interim results from its phase 1b study using Fc-fusion protein TX45 for the treatment of patients with Group 2 pulmonary ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...
Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its ...
Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein.
The TX45 treatment demonstrated significant improvements in left ventricular function and pulmonary hemodynamics, supporting the ongoing APEX Phase 2 clinical trial.
Tectonic Therapeutic, Inc.'s stock surged 120% after positive Phase 1b data for TX45 in treating PH-HFpEF, a condition with no approved therapies. TX45, an Fc-relaxin fusion protein, showed ...
The market's reaction reflects concerns over the future of TECX's lead product candidate, TX45, which targets the same RXFP1 receptor as Lilly's volenrelaxin. The termination of Lilly's volenrelaxin ...
Investing.com -- Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...
Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.